Transdermal delivery of dopaminergic agents
Author:
- 26 July 2005
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 65 (2_suppl_1) , S1-S2
Abstract
The answer to this question is “Yes, but.” Obviously, the presently marketed DA agonists are far from ideal and do not meet several of the needs of patients with PD. Their symptomatic efficacy is less than that of levodopa; they can induce adverse reactions including nausea, hypotension, somnolence, edema, psychosis, and others; they did not prove to modify the clinical progression of the disease; and they do not improve, and sometimes even exacerbate, some of the most disabling nonmotor PD symptoms such as falls, autonomic dysfunction, or dementia.3 Therefore, we need new agents. But novelty alone is simply inadequate. Novelty must be accompanied by the demonstration that any new agonist will provide some advantage or some innovation compared with the already marketed agents. We are not asking for new “me-too” drugs.Keywords
This publication has 6 references indexed in Scilit:
- Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonistsMovement Disorders, 2004
- Limitations of current Parkinson's disease therapyAnnals of Neurology, 2003
- Treatment interventions for Parkinson's disease: an evidence based assessmentThe Lancet, 2002
- EditorialMovement Disorders, 2002
- Continuous dopamine-receptor stimulation in early Parkinson's diseaseTrends in Neurosciences, 2000
- TREATMENT OF PARKINSONISM WITH BROMOCRIPTINEThe Lancet, 1974